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Problem: The CDC estimates one person every 20 minutes every day acquires an HPV-
related cancer.  Kentucky’s HPV associated cancer burden is among the highest in the nation.  
Adolescent HPV vaccination rates in Kentucky are far below HealthyPeople 2020 goals. Barriers 
are multifaceted and include provider, patient and system barriers. The AFIX model is an 
evidenced based quality improvement program that addresses key provider barriers. The USPSTF 
findings identify a gap in the literature related to AFIX methods to improve rates of adolescent 
vaccines.  
Objectives: The purpose of this study was to evaluate the effects of an intervention using 
the AFIX model and provider education focusing on the HPV vaccine as cancer prevention. Goal: 
To evaluate provider knowledge & attitudes of the HPV vaccine and evaluate the effects of 
provider education on vaccine rates.  Specific Aims: 1. Evaluate frequency of use of CDC Talking 
Points (rubric) 2. Evaluate changes in vaccination with use of rubric.  
Methods:  Utilizing the Assessment Feedback Incentives eXchange (AFIX) model, this 
quasi-experimental pilot research project included four phases: a retrospective chart review to 
establish baseline rates of HPV vaccination and a provider survey to identify barriers and 
facilitators (Phase 1), an educational intervention focused on presenting the HPV vaccine as 
cancer prevention (Phase 2), a process/outcome evaluation (Phase 3&4) to assess use and 
feasibility of the CDC talking points rubric and an outcome evaluation to assess any change in 
vaccine uptake. 
Primary outcome variable: adolescents age 11-17, with no prior history of the HPV 
vaccine receiving at least one dose.  
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Results: 63 of 100 medical records reviewed met inclusion criteria.  79% of adolescents 
received one dose of the HPV vaccine at a well-child visit. Only 34% received dose 2, and only 
8% received dose 3.  Significant demographic findings: older adolescents and non-Hispanics were 
less likely to initiate HPV vaccine. Provider survey results revealed the most commonly reported 
barrier at 80% was the HPV vaccine not being required for school entry. Participation in the 
Vaccines for children (VFC) program was the most commonly reported facilitator at 82%. The 
post-intervention process evaluation revealed 50% of the providers changed the way they 
presented the HPV vaccine to parents.  None of the providers used the CDC rubric and the most 
common barrier was not having a copy to refer to.  Two-thirds of the providers felt uptake of the 
vaccine had increased since the 2-dose series introduced.  Only 83% offer vaccine to females & 
males 100% of the time.  None of the providers feel the vaccine is accepted 100% of the time.  
Summary/Implications:  At 79%, the proportion of adolescents at HealthFirst Bluegrass 
age 11-17 with one dose of the HPV vaccine was above the statewide average of 58%.  The 
proportion with 2 and 3 doses were on par with national averages, but were still below 
benchmark. Because the baseline rates were just below the 80% goal and the provider surveys 
revealed the school requirement barrier, the PI chose to shift the focus to a policy intervention at 
the school level.  Using a CDC drafted school nurse letter to parents of adolescents, the PI 
proposed a new version of the 5
th
 grade letter to be sent to all Fayette county incoming middle 
school students.  The current letter only lists the 2 state required vaccines (Tdap, MCV) and not 
the third ACIP recommended HPV vaccine.  Given the recent change in the ACIP 
recommendation to a 2-dose regimen for young teens, this provides a prime opportunity to 
promote the HPV vaccine to Fayette county middle school students and their parents.   
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Use of the AFIX Model to Improve Adolescent HPV Vaccination: 
A Pilot Research Project  
Introduction 
Rates of Human Papillomavirus (HPV) vaccination in Kentucky (KY) are below the 
national average.  Because of the identified link between provider recommendation and increased 
rates of HPV vaccination (Smith, Stokley, Bednarczyk, Orenstein, & Omer, 2016), provider-
based  interventions such as the successful Assessment, Feedback, Incentives and Exchange 
(AFIX) program should be implemented at the local level. AFIX is a quality improvement 
program used to raise immunization coverage levels, reduce missed opportunities to vaccinate, 
and improve standards of practice at the provider level (Centers for Disease Control & 
Prevention, 2015). The AFIX program is an evidence-based intervention developed by the 
Centers for Disease Control and Prevention (CDC) which gained recognition after immunization 
coverage levels in public clinics in Georgia increased from 40% to 91% between 1986 and 2001. 
Since 1996, this intervention has become a national model program to improve immunization 
rates (LeBaron et al., 1997). The Community Preventive Services Task Force (CPSTF), a branch 
of the United States Department of Health and Human Services (US-DHHS), “strongly 
recommended” assessment and feedback methods such as AFIX in 1999, 2008, and 2015.  The 
task force’s regularly updated systematic review of the literature supports the use of the AFIX 
model.  Specific gaps in the literature identified by the CPSTF include measuring the 
effectiveness of the AFIX program on adolescent vaccines (CPSTF, 2015). This provides 
additional support for this pilot practice improvement project.   
The following manuscript will include background information on both the HPV disease 
epidemiology and the historical rates of the HPV vaccine.  Additionally, a summary of a focused 




integrative literature review provided the evidence base for the chosen AFIX design and the 
methods of this pilot research project.    The overall objectives and specific aims of the study 
were based on HealthyPeople 2020 and 2016 Healthcare Effectiveness Data and Information Set 
(HEDIS) measures for the HPV vaccine.  The phases of methodology include a retrospective 
chart audit, a baseline provider survey and educational intervention, and an outcome evaluation.  
Specific study barriers and facilitators will follow the chart audit results and data analysis.   
Finally, the practice and policy implications and areas for future research will conclude the 
manuscript. 
Background 
 According to the CDC, nearly 39,000 HPV associated cancers occur annually.  
Approximately 23,000 cases are women and 19,000 are men. Of the HPV-associated cancers, 
cervical cancer is the most prevalent in women, and oropharyngeal cancers are the most prevalent 
in men.  Nearly 90% of cervical and anal cancers, 70% of oropharyngeal, vaginal and vulvar 
cancers, and 60% of penile cancers are HPV associated (CDC, 2016).  The direct link between 
HPV and cancer led to the development of the Human Papillomavirus Quadrivalent (Types 6, 11, 
16, 18) Vaccine, Recombinant, approved in 2006.  Additionally the Human Papillomavirus 
Bivalent (Types 16 and 18) Vaccine, Recombinant was approved in 2009, and the Human 
Papillomavirus 9-valent Vaccine, Recombinant was approved in 2014 (U.S. Food & Drug 
Administration, 2016).  
Kentucky has some of the highest rates of HPV associated cancers in the United States.  
Specifically, Kentucky’s oropharyngeal cancer incidence rates rank first in men and third in 
women.  Vaginal and vulvar cancer incidences in KY rank first and second, respectively.  Penile 




cancer incidence in Kentucky is second highest in the nation.  Lastly, among the most common 
HPV related cancer, cervical, Kentucky ranks 7th highest in incidence (CDC, 2016).  Primary 
prevention methods such as the HPV vaccine can reduce this disease burden. 
In 2006, the HPV vaccine was approved by the U.S. Food and Drug Administration 
(FDA) and the national Advisory Committee on Immunization Practices (ACIP) recommended 
the vaccine be administered to females age 11-24. The HPV vaccine originally approved was a 
three dose series with doses at zero, two, and six month intervals.  In 2009, the vaccine was 
further approved and recommended for administration to adolescent males age 9-26.  Most 
recently in October of 2016, the Quadrivalent and 9-valent vaccines were approved for a reduced 
two- dose series with the second dose administered six to twelve months after dose one.   
Since 2006, the uptake and compliance rates in adolescents have increased slowly, but the 
vaccines continue to be underutilized.  HPV continues to have lower uptake than the Tetanus-
Diptheria-Pertussis (Tdap) and Meningicoccal vaccines (MCV).  NIS-teen data from 2015 reveal 
that Kentucky ranks 32
nd
 in the nation in Tdap rates with 84% of adolescents age 13-17 with > 1 
dose Tdap, 22
nd
 in the nation in MCV rates with 79% with > 1 dose MCV, and only 57.4% of 
females and 34.8 % males with > 1 dose HPV. Additionally, the most recent CDC NIS-teen data,  
released in August of 2016 reveals that Kentucky ranked 47
th
 of 50 states for 2015 in completion 
of the series or > 3 doses of HPV vaccination in males, with a rate of only 17.1%. Females with > 
3 doses are nearly double at 36.2%, and with > 2 doses 42.7% (Reagan-Steiner et al., 2016). The 
disparity between rates of Tdap, MCV and HPV reveal missed clinical opportunities since all 
three can be given at the same 11-12 year old well child visit.   Methods to increase the uptake of 
the HPV vaccine have been reported in the literature.    




Evidence base for Intervention 
 The AFIX program has its roots in the public health clinics of Georgia. In order to 
increase coverage levels to achieve national immunization goals, the Georgia Department of 
Public Health initiated a statewide program in 1986 that consisted of annual assessments of 
immunization records at its public health clinics.  Feedback was given to clinic providers and 
their staff who then devised their own interventions to improve vaccination rates.  Program 
incentives included awards and rankings of clinics by coverage level as well as poster 
presentations by successful clinics at annual immunization meetings. Other successful strategies 
included coordinating with Women, Infants, and Children (WIC) Food and Nutrition Service, 
conducting reminder/recall phone activities, and providing performance feedback to nursing 
staff.  Resulting from these combined efforts were immunization coverage levels in Georgia 
public clinics increasing from 40% to 91% between 1986 and 2001. This intervention has 
become a national model program to improve immunization rates (CDC, 2014).   
 LeBaron (1997) sought to investigate the marked increase in vaccination rates noted over 
an 8-year period.  He investigated the methods used and the outcomes to compare to national 
averages.  From 1988 – 1994 LeBaron was able to show that while Georgia’s vaccination rates 
rose from 53% to 89%, the national average from the National Health Interview Survey (NHIS) 
database rose from 53% to only 60% showing that the AFIX intervention was effective.  The 
CDC chose to adopt the Georgia model and recommend its use to all states.  In 1999, LeBaron 
expanded his research further to include other states and cities using the AFIX model.  He was 
able to show in four states (Colorado, Iowa, Louisiana and Missouri) and two large cities 
(Boston and Houston) how use of the AFIX model led to vaccine rate improvements on par with 
Georgia at five percentage points per year or a total average increase of 20% over four years.   




Appraisal of Evidence 
 Over the past several years as the focus on low rates of HPV vaccination has increased, a 
few studies correlating the AFIX model with adolescent vaccine rates have been conducted.   
An appraisal of the evidence was performed by compiling a synthesis table of the studies (see 
Table 2). These studies were important in elucidating the need for the proposed provider AFIX 
intervention. Common provider identified barriers such as time to educate, parental resistance 
and difficulty in discussing HPV as an STI were identified in four of the studies (Bruno et 
al.,2014; Bynum et al., 2014;  Ferrer, H., Trotter, C., Hickman, M., & Audrey, S. , 2014; Hull et 
al., 2014).  Perhaps the strongest evidence was the common theme of provider as facilitator in 
two of the level 1 studies (Jeudin et al., 2014; Rambout et al., 2014) and two other level 4 and 5 
studies (Reiter et al., 2014; Thomas, Strickland, Diclemente, & Higgins, 2013).  Lastly, there is 
sufficient evidence supporting the use of the AFIX model to improve rates of adolescent HPV 
vaccination.  Five total studies ranging from levels 2-7 all show statistically significant rate 
changes after implementation of an AFIX model at the provider level (Gilkey, Moss, et al., 2014; 
LeBaron et al., 1997; LeBaron et al., 1999a; Moss, Reiter, Dayton, & Brewer, 2012a;Perkins et 
al. ,2015) (see Table 2).    
 Based on a review of the available literature, there is evidence to suggest that 
implementation of provider interventions, such as the AFIX model, could improve uptake of the 
HPV vaccine in adolescents.  Part of the HealthyPeople 2020 goals is to have at least 50% of 
both public and private vaccine providers implement a method to measure their vaccination 
coverage.  The public sector is mandated to do this because they receive funds or vaccine 
directly from the government.  Vaccines for children (VFC) providers have mandated visits with 




Comprehensive Clinic Assessment Software Application (CoCASA) reports with rates of 
immunization used as feedback.  
Purpose 
 The purpose of this project was to evaluate the impact of a provider-focused educational 
intervention focusing on HPV vaccine as cancer prevention.  Primary outcome variables were 1) 
adolescents age 11-17 with no prior history of the HPV vaccine initiating the vaccine at a well-
child visit and 2) proportion of providers utilizing the CDC Talking Points.    
This pilot research project was conducted at an urban health clinic in the southern United States. 
The specific goal of the project was to increase rates of HPV vaccination among adolescents at 
the clinics through provider education and use of the AFIX quality improvement model. Specific 
Aims: 1. Evaluate frequency of use of CDC Talking Points (rubric) 2. Evaluate changes in 
vaccination with use of rubric. Hypothesis: 1. Educational session will increase use of rubric 
from 0 to 80% 2. Use of the rubric will increase initiation rates to 80%.   
This pilot research project aimed to assist a Health Resources and Services Administration 
(HRSA) granted primary care organization in the Southeast.  Improving rates of adolescent HPV 
vaccination could fulfill the HealthyPeople 2020 goal of 80% vaccination rates among 
adolescents.  Quality improvement measures such as improving vaccine rates help to fulfill 
requirements of HRSA grantees. 
Methods/Study Design 
This quasi-experimental pilot research project design included four phases: a retrospective 
chart review (Phase 1), an educational intervention (Phase 2), a process evaluation (Phase 3), and 
an outcome evaluation (Phase 4).   




The retrospective chart review was conducted on patient charts from December 15, 2015 
to February 15, 2016. Additionally, a post-intervention retrospective chart review was planned 
from December 15, 2016 to February 15, 2017. All providers volunteering to participate in the 
face-to-face educational in-service signed an informed consent prior to participation. The HPV 
vaccine is ACIP recommended at the 11-12 year old well child visit or on a catch-up schedule.  
Based on a power analysis of increasing rates from 57% to 80%, the goal was to review at least 
100 medical records.  The data collected during the chart review included patient age, gender, 
race, and insurance type.  Other data included was if counseling on the vaccine was provided and 
by whom, if the vaccine was offered, if it was accepted/declined/deferred by the patient, if the 
series was initiated, and if it was completed.  No patient identifying information was included. 
All pediatric and family providers practicing in the clinic were asked to participate in the 
survey and educational session.  An email with a survey cover letter was sent to all providers in 
the clinic. The survey was administered via REDCap, and all survey results were kept 
anonymous.  For the educational session, the PI asked for volunteers and distributed informed 
consents at a provider staff meeting prior to the scheduled educational session.  Participation in 
the educational session was also voluntary. 
Research Procedures 
  For the retrospective chart review, the PI assessed the FQHC clinic practices regarding 
HPV vaccine rates. Specifically, the PI examined 100 electronic medical records to assess the 
proportion of HPV vaccines that were administered to adolescents between 11-17 years of age.  
The clinic provided a list of patient medical record numbers for patients ages 11-17 that 
presented to the FQHC clinic for routine well-child exams (V20.2) between December 15, 2015 




and February15, 2016.  No one other than the PI had access to the list of medical record 
numbers, and the list was kept in a locked file cabinet drawer in the clinic.  Only the PI had this 
key.  Once the electronic medical records were accessed, the list of medical record numbers was 
destroyed per the clinic’s HIPAA policy.  Participants included all males and females age 11-17 
with encounter for a well-child visit with vaccines (ICD-9 codes V20.2, V04.89, V05.8 and CPT 
code 90649).  Patients were excluded if they initiated the HPV vaccine before the current 11-17 
year old well-child visit. 
Survey/ Educational Intervention 
Before initiating the educational phase, an online REDcap survey and cover letter on the 
HPV vaccine was distributed to all pediatric providers at the clinic via email. An educational 
session on the CDC Talking Points evidence based rubric was presented at several lunchtime 





completing the informed consent.  This educational session was part of the Incentives component 
of the AFIX program.  Providers were then asked to trial use of the CDC script in their 
adolescent visits. 
Process/Outcome Evaluation  
To determine feasibility and sustainability of the intervention, anonymous provider 
surveys sent via REDcap were completed voluntarily two months after the intervention 
(educational session).  Providers were asked to report on whether they are using the CDC talking 
points, and if so, how often; if not, they were asked to disclose the barriers (see Appendix G). 




The final planned step of this pilot research project was a measurement of the proportion 
of HPV vaccination rates in 11-17 year olds two months after the intervention. This was to be 
completed using the same electronic medical record review process and inclusion/exclusion 
criteria to determine baseline rates of HPV vaccination. One hundred to 200 medical records 
were originally proposed for the outcome evaluation from December 15, 2016- February 15, 
2017.  The quantity of records (100-200) was based on the original power analysis to increase 
the proportion from 57% to 80%.  Because the baseline rates were 79%, a revised power analysis 
indicated that 600 records would be needed to detect a significant change in vaccine rates given 
the goal of 80%.  In two months time 600 well visits for 11-17 year olds would not be generated. 
Therefore, the outcome evaluation of vaccine rates was not completed. 
Data collection/analysis 
 All data was collected in Redcap, a secure online research database.  The database was  
analyzed using statistical SPSS software version 23.0 using crosstabs with frequencies, 
percentages and chi-squared analysis.  Significant findings were reported at p  > .05. 
Results 
Retrospective medical record review of 100 electronic medical records revealed the 
following descriptive data:  63 met inclusion criteria of no prior history of the HPV vaccine; 
79% (n=50) initiated/accepted the HPV vaccine; only 34% (n=17) received the 2
nd
 dose, and 
only 8% (n=4) completed the series with the third dose.  Uptake of the HPV vaccine was broken 
down into the following demographic categories: age, gender, race, ethnicity and insurance 
coverage (see Table 1).  Significant findings included age and ethnicity.  Adolescents accepting 
the HPV vaccine were significantly younger than those who declined to initiate vaccination 
(M=13.1, SD=2.0 versus M=14.5, SD=2.1; p =.024).  Non-Hispanics (69%) were significantly 




less likely (p=0.012) to initiate the HPV vaccine compared with Hispanics (92%). Gender, race 
and insurance status were non-significant. 
 Baseline surveys were distributed to 14 pediatric providers, and 11 providers 
participated.  Questions were posed related to the provider practice of offering the HPV vaccine 
and provider perception of HPV vaccine uptake.  Additional survey questions evaluated provider 
identified barriers and facilitators to uptake.   
A majority of providers or 63% (n=7) report offering the HPV vaccine 100% of the time 
to females and males, 27% (n=3) offer females and males the vaccine 75-99% of the time, and 
just 10% (n=1) offer it 50-74% of the time.   Provider perception of vaccine uptake by gender 
was more varied.  Only 27% (n=3) of providers reported that females initiated HPV vaccine 75-
99% of the time, whereas the remaining 73% (n=8) reported female uptake as 50-74%.  Male 
uptake of the vaccine was reported as lower, with only 27% (n=3) reporting 75-99%, 44% (n=5) 
reporting 50-74%, 18% (n=2) reporting 25-49%, and <10% (n=1) reporting 0-24% of male 
uptake (see Tables 2-5).    
The most commonly reported barrier by just over 80% (n=8) of providers was not having 
the HPV vaccine as a requirement for middle school entry.  Most frequent provider reported 
facilitators were participating in the VFC program 82% (n=9) and having the time to educate 
patients about the HPV vaccine 73% (n=8).   
  Provider survey results revealed that 50% of providers (n=3) changed the way they 
presented the vaccine, although none of them reported using the CDC Talking Tips.  The most 
commonly reported barrier was not having a copy of the CDC Talking Tips available.  Lastly, as 
discussed previously, the outcome evaluation of a change in vaccine rates was not completed due 




to baseline proportion of 79% with a power analysis of > 600 EMRs needed to detect a 
statistically significant change to the goal of 80%.   
Discussion 
Major findings 
The retrospective record review revealed that 79% of the FQHC’s adolescents age 11-17 
with no prior history of the HPV vaccine initiated/accepted the vaccine at a well-child visit.  This 
was just below the goal of 80% based on HealthyPeople 2020 goals.  Uptake of doses 2 and 3 
were significantly lower at 34% and 8% respectively. Significant demographic correlations 
included both age and ethnicity. The younger the patient the more likely they were to accept dose 
1 of the HPV vaccine. This finding is potentially based on the increase in well child visits at age 
11-12 for adolescents to get the school required physical and Tdap and MCV immunizations.  
This study’s results are different from Bynum et al. (2014) and Reiter et al. (2014) who found 
that older adolescents age 13-14 were more likely to initiate the vaccine. Additionally, Hispanic 
patients were more likely to accept /initiate the vaccine than non-Hispanic patients.  This mirrors 
the 2015 NIS-teen data revealing Hispanic males & females having higher uptake of the HPV 
vaccine over non-Hispanics (CDC, 2016).   Baseline provider survey results highlighted the 
barrier of the HPV vaccine not being required for school entry, as well as providers being less 
likely to offer the vaccine to males over females.  The post-intervention survey revealed that 
50% of respondents (n=6) changed the way they present the HPV vaccine to patients.  None of 
the providers used the CDC rubric specifically, and the most commonly reported barrier to this 
was not having a copy of the rubric available.   
 
 





  Barriers encountered were mostly logistical in nature.  Initially, the PI planned to have an 
educational session (the study intervention) for all pediatric providers at one or two staff 
meetings.  The pediatric providers work at two main clinics and seven school-based clinics.  This 
group only meets every other month, and the adult providers (not part of the study population) 
are also at those meetings.  Additionally, as part of an accreditation process, this FQHC had an 
Operational Site Visit (OSV) scheduled in early December, so all staff meetings for the month 
were cancelled.   
Consequently, the intervention phase was several either individual or small group 
meetings to present the CDC Talking Points rubric.  This shift in methodology actually became a 
facilitator because of the small group or individual environment.  Several of the providers were 
able to verbalize their frustrations at the HPV vaccine not being required for school entry as a 
significant barrier to the vaccine’s uptake.  Additionally, the PI was able to review the new 
Vaccine Information Statement (VIS) with the 2-dose ACIP regimen just released December 2
nd
, 
2016.  A few providers were unaware of the 2-dose series until it was presented.   The providers 
at the seven school based clinics were also not together for a meeting during the proposed 
educational phase of the study.  Several, but not all, of the school based pediatric providers 
completed the online survey.  Rather than a face to face educational intervention, the PI 
distributed the CDC Talking Points rubric and the CDC slide-set to the seven school based 
providers via email as they were not available in the last two weeks of December because of 
School Clinic closings.    
Other facilitators of this pilot study were guideline based and patient education/ outreach 
based.  At the time of the study intervention (mid-December), the new CDC/ ACIP 




recommendation for a 2-dose regimen for 11-15 year olds was released.   The new VIS, dated 
12/2/2016, was distributed to providers and nurses, but practice dissemination had not yet 
occurred.  This provided an additional incentive for the PI to encourage providers to recommend 
the new 2-dose HPV series to adolescents.  Additionally, the VFC program distributed large, 
stand-up life size posters of a boy and a girl with the logo “If there were a vaccine against cancer 
wouldn’t you give it to me?”  At the time of the provider intervention, the two main clinics of the 
FQHC had these life-size posters in their lobbies. Only one of the school clinics had the posters 
displayed.   
Practice Implications 
Based on the results of the medical record review and provider survey, several practice 
and policy recommendations can be made. Specifically, the provider survey highlighted the 
perception that males initiate the HPV vaccine less often than females.  Implications include the  
need to make a concerted effort targeting males especially since their rates of cancer are 
comparable (CDC, 2016).  This perception could lead to providers’ hesitation to strongly 
recommend the HPV vaccine to males as well as females.  The objective data from the 
retrospective record review revealed that males had a slightly higher uptake over females, 
possibly suggesting recommendation to females should be stronger.  Other demographic data 
that could influence practice habits relate to ethnicity and insurance status.  Non-Hispanics and 
those with Medicaid or no insurance were less likely to initiate the vaccine.  The latter group is 
the population eligible for free vaccine from the VFC program.  According to the provider 
survey of patient facilitators, awareness of the VFC program ranked lowest with only 36% (n=4) 
of providers believing their patients were aware of the availability of free vaccines.  This 
combination of data indicates a practice gap for promoting patient awareness of the VFC 




program.  Another possible area for practice change is EMR prompts or reminders.  Only one 
provider indicated that EMR prompts/ reminders influenced HPV vaccine rates.   
  Upon review of patients missing the HPV vaccination, a check of the Kentucky 
Immunization Registry (KYIR) found several records of either HPV vaccine initiation or 
completion.  These records had not been either scanned into the EMR or manually entered as 
historical into the immunization record.  A process recommendation to the clinic manager, 
CMAs and nurses will be that a designated person check the KYIR weekly for all scheduled well 
child visits to ensure up to date records.  
Policy Implications 
According to Bynum et al. (2014) survey results of provider-identified barriers can be 
utilized in development of interventions to increase vaccination rates.  The provider survey 
results from this study reveal that the lack of a school mandate is a significant barrier.  Efforts 
nationwide to school mandate the HPV vaccine have been poorly received.  Unfortunately, in 
Kentucky there have been several failed legislative attempts for HPV vaccine education or a 
school mandate for adolescents to obtain the HPV vaccine (National Council of State 
Legislatures, 2017).  To date, only two states and the District of Columbia have a school 
mandate for the HPV vaccine.  While legislation mandating this may not be realistic at this point, 
an alternate strategy would be to include an endorsement by both the school nurses and 
principals on the school letters sent home to all incoming middle school students.   The CDC as 
well as the National Association of School Nurses (NASN) have the same adolescent vaccine 
letter template (see Appendix F) posted as a policy initiative for school districts (CDC, 2016; 
National Association for School Nurses, 2015).  The PI proposed that this letter replace the 




current school letter distributed to all rising 6
th
 graders.   The letter currently in use only lists the 
two adolescent vaccines required by Kentucky Statute (Tdap and MCV), but omits the 
CDC/ACIP recommended HPV vaccine.  A key component of the proposed letter is the focus of 
the HPV vaccine as cancer prevention.  Additional strength to this letter will be the new 2-dose 
regimen CDC/ACIP approved December 2, 2016 for adolescents age 11-15.   The PI amended 
the CDC letter to include the 2-dose regimen, as the online school letter template did not reflect 
this change.  This letter was proposed to the school district health coordinator in a meeting on 
February 23, 2017.  The district health coordinator approved the nurse and principal letter for 
distribution this spring and summer to all incoming middle school students. 
Summary 
 The burden of HPV associated cancers in Kentucky is among the highest in the country.    
Additionally, the rates of HPV vaccination continue to be far below the nationwide averages.  
Although Kentucky’s initiation rates are low, this pilot study revealed an FQHC with initiation 
rates near HealthyPeople 2020 goals.   Provider identified barriers and facilitators influenced the 
practice and policy implications. The most commonly reported barriers at just over 80% (n=9) 
were the lack of a school mandate for the HPV vaccine and the fact that patients are unlikely to 
return for doses 2 and 3.   Objective data supported the providers’ subjective data as only 34% of 
patients returned for dose 2 and only 8% for dose 3.  Based on this, a policy initiative to increase 
all three ACIP adolescent vaccines was proposed to the Fayette county district health coordinator 
in late February.  A nurse letter, principal letter and text message reminders for all 3 ACIP 
recommended adolescent vaccines will be initiated this spring. 




Future research could assess the impact of the school based campaign as well as the new 
2-dose series.  Because of the provider reported barrier of returning for doses 2 and 3, a follow-
up study at the FQHC could include an assessment of completion rates with the new 2-dose 
regimen versus completion rates with the 3-dose regimen.   
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Table 1. Demographic characteristics by HPV vaccination (N=63) 
 Total sample 
 
 
n = 63 







Age  13.1 (2.0) 14.5 (2.1) .024* 
Sex 
   Male 
   Female 





22 (72%)  








   White 
   Black 
















   Hispanic 





















5  (100%) 
36 (78%) 
9   (82%) 
 
0  (0%) 
10 (22%) 
2   (18%) 
 
>.05 
*significance at level p <.05  
 





Table 2.  Provider Survey Results (n=11) offer vs. accept/initiate HPV vaccine 
 
100% 75-99% 50-74% 25-49% 
How often offer HPV vaccine to females 11-17 7 3 1 0 
How often offer HPV vaccine to males age 11-17 7 3 1 0 
How often do females accept/initiate 0 3 8 0 



























Participates in the VFC program 9 11 
Have the time to educate patients about the HPV vaccine 8 11 
Reminders within the EMR for the HPV vaccine 1 11 























Table 4. Provider reported practice barriers (n=11) 
 Yes  Total 
I do not have the time to discuss HPV vaccination  
during visits 
2 11 
Practice not adequately reimbursed for HPV vaccine 1 11 








Table 5. Provider reported patient barriers (n=11) 
Unaware of the risks of HPV 4 11 
Think the cost of the HPV vaccine is too high 0 11 
Worried about long-term safety of the vaccine 0 11 
Unlikely to return for 2nd and 3rd dose 7 11 
Unlikely to get vaccine because it is not required for 
school entry 
8 11 
Concerned about the pain associated with the vaccine 1 11 
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Key Terms and Abbreviations: 
AFIX = Assessment, Feedback, Information and Exchange  
CDC = Centers for Disease Control 
CI = Confidence Interval 
DV = Dependent variable 
HPV = Human Papillomavirus 
IV = Independent variable 
ITS = Interrupted time series study 
MCV = Meningicoccal vaccine 
NIS = National Immunization Survey 
RCT = Randomized controlled trial 
SR = Systematic review 
Tdap = Tetanus, diptheria and pertussis vaccine 
measurable 
improvemen
ts in HPV 
vaccine rates 
in a large 
population 
































Level I: Systematic 






           








         
Level III: Controlled 
trial without 
randomization 
             
Level IV: Case-
control or cohort 
study 






      
Level V:  SR of 
qualitative or 
descriptive studies 
        
X 













Level VII:  Expert 
opinion or consensus 
             
X 
 
Key to Synthesis table 
1 - (Jeudin et al., 2014) 2 - (Rambout et al., 2014) 3 - (Gilkey, Dayton, et al., 2014b) 4 - (Perkins, 2014) 
5 - (LeBaron et al., 1997) 6 - (LeBaron et al., 1999b) 7 - (Reiter et al., 2014) 8 - (Ferrer et al., 2014) 
9 - (Bruno et al., 2014) 10 - (Bynum et al., 2014) 11 - (Hull et al., 2014) 12 - (Thomas et al., 2013)  13 - (Moss et al., 2012a) 
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analysis 














At the patient’s 11-17 year old well-child visit, were the following documented: 
 
 
Information Yes No Comments 
Was counseling 




By: ___ CMA 
      ____NP/MD 
  
Was the HPV 
vaccine offered? 
 
   
Patient’s response 






Was the HPV 
vaccine series 
initiated? 
   
Was the vaccine 
series initiated or 
completed prior 
to this visit? 
   
Were the other 
ACIP 
recommended 
vaccines (Tdap & 
MCV) given?  
   
 
Doses given (Y/N)? #1_________  #2__________  #3___________ 










Appendix B. Provider Survey/Questionnaire  
Please answer the following questions by selecting the answer that best represents your experience as a provider: 
1.  How often do you offer the HPV vaccine during routine well-child exams for 11-12 year old FEMALES? 
 100%  25-49% 
 75-99%  0-25% 
 50-74% 
 
2.    How often do you offer the HPV vaccine during routine well-child exams for 11-12 year old MALES? 
 100%  25-49% 
 75-99%  0-25% 
 50-74% 
 
3.  When offered, what percentage of your FEMALE patients accept HPV vaccination: 
 100%  25-49% 
 75-99%  0-25% 
 50-74% 
 
4.  When offered, what percentage of your MALE patients accept HPV vaccination: 
 100%  25-49% 
 75-99%  0-25% 
 50-74% 
 
Which of these factors affect your decision to recommend the HPV vaccine in your current practice?  Please select 
all that apply: 
Practice Facilitators Practice Barriers 
 My practice participates in the Vaccines 
for Children (VFC) program. 
 The HPV vaccine is not stocked or there is low 
availability in my practice. 
 My clinic has reminders within the 
EMR for HPV vaccination. 
 My practice is not adequately reimbursed for HPV 
vaccine administration. 
 My clinic uses a form during well-child 
exams that prompts for CDC 
recommended vaccinations. 
 I do not have time to discuss HPV vaccination 
during patient visits. 
 I have time to educate my patients about 





  Continued on next page…… 
Which of these factors affect your decision to recommend the HPV vaccine in your current practice?  Please select 
all that apply: 




Provider Facilitators Provider Barriers 
 I strongly recommend the HPV vaccine 
to all eligible patients. 
 I have concerns about the long-term safety of the 
HPV vaccine. 
 I have completed continuing education 
regarding HPV and/or the HPV vaccine. 
 I feel uncomfortable discussing a vaccine for a 
sexually transmitted infection with my patients 
and/or their parents. 
 I am aware of the CDC/ACIP 
recommendations for HPV vaccination. 
 I do not agree with the CDC/ACIP 





Patient Facilitators Patient Barriers 
 My patients have a good understanding 
of the risks of HPV infection. 
 My patients are unaware of the risks of HPV 
infection. 
 My patients/their parents believe that 
they are at risk for HPV. 
 My patients think the cost of the HPV vaccine is too 
high. 
 My patients have a belief in primary 
prevention. 
 My patients are worried about the long-term safety 
of the HPV vaccine. 
 My patients are aware of the Vaccines 
for Children (VFC) program and its 
coverage. 





 dose of the vaccine series. 
 My patients have positive peer/family 
support regarding HPV vaccination. 
 My patients are unlikely to get the vaccine because 
it is not required for school entry. 
Other:   My patients are concerned about the pain 




Please answer the following questions about the CDC/ACIP recommendations for HPV vaccination to the best of 
your knowledge: 
8.  What is the recommended interval for HPV vaccination? Check all that apply 
a.  0, 3, and 6 months   
b.  0, 1-2, and 6 months 
c.  0, and 6-12 months 
d.  0, 6, and 9 months 
 
 
          Continued on next page…  
 
 




9.  What is the ideal age of vaccination for males and females? 
a.  ages 11-12, can be given as early as 9 
b.  ages 13-15, can be given as early as 11 
c.  ages 9-13, can be given as early as 9 
d.  ages 15-18, can be given as early as 9 
10. What are the recommendations for catch-up vaccination for males and females? 
a.  Catch-up for unvaccinated men and women ages 13-18. 
b.  Catch-up for unvaccinated men and women ages 13-21. 
c.  Catch-up for unvaccinated men ages 13-21 (and up to 26 for special populations), catch-up for women 13-26. 
d.  Catch-up for unvaccinated men ages 15-21 (and up to 26 for special populations), catch-up for women 15-26. 
 
 
Comments: Please feel free to share any comments or ideas you have related to the HPV vaccine 
















































Appendix E – proposed 5th grade school letter with 6th grade health requirements (Principal) 
Dear Parent/Guardian, Your student will be enrolling in the 6th grade next year and will need the following 
on file prior to starting school. Per 902 KAR 2:060 a student cannot attend school without this 
documentation.  
1. A school Physical Examination is required for 6th grade entry.  
 
(Done within one calendar year of enrollment. The KHSAA Sports Physical Form & Consent is a different 
form and cannot be substituted.)  
 
2. A current, updated Kentucky Immunization Certificate, including all previously required 
immunizations and the following 6th grade requirements.  
 
* One dose of Tdap regardless of interval since last dose of Tetanus-containing vaccine will be required 
for students at 6th grade entry, with option of Td for individuals who cannot receive Pertussis-containing 
vaccine.  
 
* Two (2) doses Varicella or proof of history of Chicken Pox. (Proof of Chicken Pox (Varicella) disease in 
lieu of immunization must now be in the form of a diagnosis of typical Varicella disease or verification of a 
history of Varicella disease or Herpes Zoster disease by a healthcare provider.)  
 
* One dose of Meningococcal vaccine (MCV) for 6th grade entry. The use of Meningococcal Conjugate 
Vaccine is preferred, but Meningococcal Polysaccharide Vaccine (MPSV) may be used if the conjugate 




 grade recommended vaccines: 
• HPV vaccine is recommended for preteens at age 11 or 12 to protect against cancers and 
other diseases caused by HPV infection. Both boys and girls should receive 2 doses of HPV vaccine to 
protect against these serious diseases. Your preteen should receive the second dose 6-12 months after 
the first dose. 
 
3. If your student is going to play sports in middle school, they will need a KHSAA Sports Physical Form 
& Consent completed by you and your Healthcare Provider. The form is available online through 
www.fcps.net  
 
Please return your student’s forms as soon as you’ve had the appointment with your Healthcare Provider. 
If you complete these requirements over the summer, please bring the forms to your student’s middle 
school prior to the first day of school.  
 





School Principal            Date  
  
  




Appendix F. School Nurse Letter 
 
[INSERT NURSE NAME], School Nurse 
[INSERT SCHOOL ADDRESS] 
 
[INSERT CURRENT DATE] 
 
Dear Parent or Guardian: 
 
As your child’s school nurse, I want to remind you of the importance of getting your son or daughter 
vaccinated before they go back to school this fall. Vaccines are the best way you can protect your child 
from a number of serious diseases, including cancers caused by HPV. 
 
As you are making your back-to-school checklist for your preteen, I encourage you to make sure your 
sons and daughters get all the vaccines that are recommended for them. Schedule your child’s 
appointment today to ensure they are up-to-date on the vaccines they need. The Centers for Disease 
Control and Prevention (CDC) and the Advisory Committee on Immunization Practices recommend your 
son or daughter receive the following vaccines: 
 Quadrivalent meningococcal conjugate vaccine is recommended for preteens at age 11 or 12 for 
protection against bacteria that cause meningococcal disease, a very serious illness which can 
lead to death in as little as 48 hours. A second shot is recommended for teens at age 16 to 
continue providing protection. 
 HPV vaccine is recommended for preteens at age 11 or 12 to protect against cancers and other 
diseases caused by HPV infection. Both boys and girls should receive 2 doses of HPV vaccine to 
protect against these serious diseases. Your preteen should receive the second dose 6-12 
months after the first dose. 
 One dose of Tdap vaccine is recommended for preteens at age 11 or 12 to continue providing 
protection against tetanus, diphtheria, and pertussis (whooping cough). 
 Preteens and teens should also get the flu vaccine every year, ideally as soon as the vaccine is 
available.  
 
Kentucky requires Meningococcal and Tdap for school entry; to learn more about state immunization 
requirements, go to: www.immunize.org/laws. 
 
Protect your preteen and talk with your child’s clinician about what vaccines they need. You may also 
contact me with any questions. I can be reached at [PHONE NUMBER] and I am in my office [INSERT 
OFFICE HOURS FOR VISITS].  I can also provide you with additional resources about vaccination and 
other health topics for the preteen and teen years. To learn more about adolescent vaccines, please visit 
CDC’s Vaccines for Preteens and Teens website at www.cdc.gov/vaccines/teens. 
 
Sincerely,  
[INSERT NAME OF SCHOOL NURSE]  
Your School Nurse 
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